Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTL003
- Development stage
- Preclinical
- Lead developer
- Genkyotex
- Modality
- Recombinant Proteins and Enzymes
01
Overview
**GTL003** is Genticel's proprietary reengineered adenylate cyclase derived from the Bordetella pertussis CyaA protein, developed as an antigen for multivalent acellular vaccines. It leverages Genticel's Vaxiclase platform to enhance immune responses against infectious diseases, particularly whooping cough (pertussis), by acting as a carrier or standalone antigen in combination vaccines. In 2016, preclinical in vivo studies successfully met predefined objectives, triggering a milestone payment from partner Serum Institute of India, enabling progression toward formal preclinical testing ahead of clinical development for emerging markets.[1][3]
Beyond the preview
Go deeper on GTL003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTL003.